Mintzer J, Lanctôt KL, Scherer RW, et al. - Methylphenidate was compared with placebo in lowering the severity of apathy in individuals with Alzheimer disease.

• A randomized clinical trial of 200 participants.

• Relative to placebo, methylphenidate appeared safe and was linked with a reduction in apathy symptoms as assessed by the Neuropsychiatric Inventory within 2 months that was sustained for 6 months.

• Overall, in individuals with Alzheimer disease, apathy can be managed by using methylphenidate, which in turn can decrease symptoms and caregiver burden. .